Bioengineering, Rice University, Houston, Texas 77030, United States.
NuProbe USA, Houston, Texas 77054, United States.
Anal Chem. 2022 Jan 18;94(2):934-943. doi: 10.1021/acs.analchem.1c03716. Epub 2021 Dec 21.
Clinically and biologically, rare DNA sequence variants are significant and informative. However, existing common detection technologies are either complex and time-consuming in workflow, or restricted in the limit of detection (LoD), or do not allow for multiplexing. Blocker displacement amplification (BDA) method can stably and effectively detect and enrich multiple rare variants with LoD around 0.1% variant allele fraction (VAF). Nonetheless, the detailed mutation information has to be identified by additional sequencing technologies. Here, we present allele-specific BDA (As-BDA), a method combining BDA with allele-specific TaqMan (As-TaqMan) probes for effective variant enrichment and simultaneous single nucleotide variant or small insertions and deletions (INDELs) profiling. We demonstrated that As-BDA could detect mutations down to 0.01% VAF. Further, As-BDA could detect up to four mutations with low to 0.1% VAF per reaction using only 15 ng DNA input. The median error of As-BDA in VAF determination is approximately 9.1%. Comparison experiments using As-BDA and droplet digital PCR on peripheral blood mononuclear cell clinical samples showed 100% concordance for samples with mutations at ≥ 0.1% VAF. Hence, we have shown that As-BDA can achieve simultaneous enrichment and identification of multiple targeted mutations within the same reaction with high clinical sensitivity and specificity, thus helpful for clinical diagnosis.
从临床和生物学角度来看,稀有 DNA 序列变异具有重要意义和信息价值。然而,现有的常见检测技术要么在工作流程中复杂且耗时,要么在检测限(LoD)方面受到限制,或者不允许多重检测。阻断剂置换扩增(BDA)方法可以稳定有效地检测和富集多个稀有变体,其 LoD 约为 0.1%的变异等位基因分数(VAF)。然而,详细的突变信息必须通过额外的测序技术来识别。在这里,我们提出了等位基因特异性 BDA(As-BDA),这是一种将 BDA 与等位基因特异性 TaqMan(As-TaqMan)探针相结合的方法,用于有效富集变体并同时进行单核苷酸变异或小插入和缺失(INDELs)分析。我们证明 As-BDA 可以检测到低至 0.01%VAF 的突变。此外,使用仅 15ng DNA 输入,As-BDA 可以在每个反应中检测到多达四个低至 0.1%VAF 的突变。As-BDA 在 VAF 测定中的中位误差约为 9.1%。使用外周血单核细胞临床样本,通过 As-BDA 和液滴数字 PCR 进行的比较实验显示,对于 VAF 大于等于 0.1%的突变样本,两种方法的一致性为 100%。因此,我们已经证明,As-BDA 可以在同一反应中同时实现多个靶向突变的富集和鉴定,具有很高的临床灵敏度和特异性,从而有助于临床诊断。